146 related articles for article (PubMed ID: 6427791)
1. Inhibition of thromboxane synthetase by OKY-1581 stimulates the formation of PGE2, PGF2 alpha, PGD2 and 6-keto-PGF1 alpha in human platelets.
Uotila P; Matintalo M
Prostaglandins Leukot Med; 1984 Apr; 14(1):41-6. PubMed ID: 6427791
[TBL] [Abstract][Full Text] [Related]
2. The effects of aspirin and OKY-1581 on the metabolism of exogenous arachidonic acid in rat alveolar macrophages.
Punnonen K; Uotila P; Mäntylä E
Res Commun Chem Pathol Pharmacol; 1984 Jun; 44(3):367-74. PubMed ID: 6431566
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological studies on the TXA2 synthetase inhibitor (E)-3-[p-(1H-imidazol-1-ylmethyl)phenyl]-2-propenoic acid (OKY-046).
Hiraku S; Taniguchi K; Wakitani K; Omawari N; Kira H; Miyamoto T; Okegawa T; Kawasaki A; Ujiie A
Jpn J Pharmacol; 1986 Jul; 41(3):393-401. PubMed ID: 3093741
[TBL] [Abstract][Full Text] [Related]
4. The effect of a thromboxane synthetase inhibitor, OKY-046, on urinary excretion of immunoreactive thromboxane B2 and 6-keto-prostaglandin F1 alpha in patients with ischemic cerebrovascular disease.
Uyama O; Nagatsuka K; Nakabayashi S; Isaka Y; Yoneda S; Kimura K; Abe H
Stroke; 1985; 16(2):241-4. PubMed ID: 3883580
[TBL] [Abstract][Full Text] [Related]
5. Protective actions of a new thromboxane synthetase inhibitor in arachidonate induced sudden death.
Edmonds LC; Lefer AM
Life Sci; 1984 Oct; 35(17):1763-8. PubMed ID: 6434893
[TBL] [Abstract][Full Text] [Related]
6. The relation between thromboxane and prostaglandin synthesis in human decidua tissue: a comparison of eicosanoid synthesis in minced tissue with that in a cell-free preparation.
Asbóth G; Gimes G; Hertelendy F; Tóth M
Biochim Biophys Acta; 1989 Mar; 1002(1):101-8. PubMed ID: 2493805
[TBL] [Abstract][Full Text] [Related]
7. Prostaglandin and thromboxane synthesis by M5076 ovarian reticulosarcoma during growth: effects of a thromboxane synthetase inhibitor.
Chiabrando C; Broggini M; Castelli MG; Cozzi E; Castagnoli MN; Donelli MG; Garattini S; Giavazzi R; Fanelli R
Cancer Res; 1987 Feb; 47(4):988-91. PubMed ID: 3100032
[TBL] [Abstract][Full Text] [Related]
8. Arachidonic acid induced platelet aggregation and thromboxane formation is inhibited by OKY-1581.
Uotila P; Matintalo M; Dahl ML
Prostaglandins Leukot Med; 1983 Nov; 12(3):299-303. PubMed ID: 6419237
[TBL] [Abstract][Full Text] [Related]
9. Effect of thromboxane A2 synthetase inhibition, singly and combined with thromboxane A2/prostaglandin endoperoxide receptor antagonism, on inositol phospholipid turnover and on 5-HT release by washed human platelets.
de Chaffoy de Courcelles D; De Clerck F
Eur J Pharmacol; 1990 Mar; 188(2-3):161-9. PubMed ID: 2318257
[TBL] [Abstract][Full Text] [Related]
10. Biosynthesis of lipoxygenase and cyclo-oxygenase products from [14C]-arachidonic acid by human colonic mucosa.
Boughton-Smith NK; Hawkey CJ; Whittle BJ
Gut; 1983 Dec; 24(12):1176-82. PubMed ID: 6416934
[TBL] [Abstract][Full Text] [Related]
11. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro.
De Clerck F; Beetens J; de Chaffoy de Courcelles D; Freyne E; Janssen PA
Thromb Haemost; 1989 Feb; 61(1):35-42. PubMed ID: 2546278
[TBL] [Abstract][Full Text] [Related]
12. Effect of OKY-046, a thromboxane A2 synthetase inhibitor, on arachidonate-induced platelet aggregation: possible role of "prostaglandin H2 steal" mechanism.
Kuzuya T; Hoshida S; Yamagishi M; Ohmori M; Inoue M; Kamada T; Tada M
Jpn Circ J; 1986 Nov; 50(11):1071-8. PubMed ID: 3102802
[TBL] [Abstract][Full Text] [Related]
13. Effects of OKY 1581 on bronchoconstrictor responses to arachidonic acid and PGH2.
Tilden SJ; Underwood DC; Cowen KH; Wegmann MJ; Graybar GB; Hyman AL; McNamara DB; Kadowitz PJ
J Appl Physiol (1985); 1987 May; 62(5):2066-74. PubMed ID: 2954941
[TBL] [Abstract][Full Text] [Related]
14. Prevention of endotoxin-induced pulmonary hypertension in primates by the use of a selective thromboxane synthetase inhibitor, OKY 1581.
Casey LC; Fletcher JR; Zmudka MI; Ramwell PW
J Pharmacol Exp Ther; 1982 Aug; 222(2):441-6. PubMed ID: 6896528
[TBL] [Abstract][Full Text] [Related]
15. U-60,257 has no effect on the metabolism of arachidonic acid in nonstimulated human polymorphonuclear leukocytes.
Dahl ML; Puustinen T; Uotila P
Res Commun Chem Pathol Pharmacol; 1984 Jun; 44(3):355-65. PubMed ID: 6431565
[TBL] [Abstract][Full Text] [Related]
16. Effects of thromboxane synthetase inhibition on arachidonate metabolism and platelet behaviour.
Parry MJ
Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):23S-29S. PubMed ID: 6401997
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological studies on OKY-1581: a selective thromboxane synthetase inhibitor.
Hiraku S; Wakitani K; Katsube N; Kawasaki A; Tsuboshima M; Naito J; Ujiie A; Komatsu H; Iizuka K
Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():241-4. PubMed ID: 6221530
[No Abstract] [Full Text] [Related]
18. [Beneficial effect of a selective TXA2 synthetase inhibitor, OKY-046, both on thromboxane B2 production and vascular damage after spinal cord injury in rat spinal cord].
Morimoto K; Ikata T; Tounai T
Nihon Seikeigeka Gakkai Zasshi; 1990 Jan; 64(1):82-8. PubMed ID: 2319197
[TBL] [Abstract][Full Text] [Related]
19. Intravenous infusion of a selective inhibitor of thromboxane A2 synthetase in man: influence on thromboxane B2 and 6-keto-prostaglandin F1 alpha levels and platelet aggregation.
Yui Y; Hattori R; Takatsu Y; Nakajima H; Wakabayashi A; Kawai C; Kayama N; Hiraku S; Inagawa T; Tsubojima M
Circulation; 1984 Oct; 70(4):599-605. PubMed ID: 6434196
[TBL] [Abstract][Full Text] [Related]
20. Pharmacologic inhibition of thromboxane synthetase and platelet aggregation: modulatory role of cyclooxygenase products.
Bertelé V; Falanga A; Tomasiak M; Chiabrando C; Cerletti C; de Gaetano G
Blood; 1984 Jun; 63(6):1460-6. PubMed ID: 6426554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
